Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
received:
15
05
2023
accepted:
31
10
2023
revised:
24
10
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
aheadofprint
Résumé
Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-positive women. We conducted a systematic review and meta-analysis assessing the accuracy of HPV-E6/E7-oncoprotein tests to detect underlying cervical-precancer and cancer. We included studies reporting data on oncoprotein test accuracy detecting cervical intraepithelial neoplasia grade 3 or worse. Random effects logistic regression models were applied for pooling absolute and relative accuracy. Twenty-two studies were included. Sensitivity and specificity estimates ranged from 54.2% (95%CI: 45.2-63.0) to 69.5% (95%CI:60.8-76.9) and from 82.8% (95%CI: 50.4-95.8) to 99.1 (95%CI: 98.8-99.3), respectively in the population irrespective of HPV status. Higher sensitivity estimates ranging from 60.8% (95%CI: 49.6-70.9) to 75.5% (95%CI: 71.7-78.9) but lower specificity estimates ranging from 83.7% (95%CI: 76.1-89.3) to 92.1% (95%CI: 88.5-94.6) were observed in studies enrolling high-risk-HPV-positive women. Studies recruiting only HIV-positive women showed a pooled sensitivity of 46.9% (95%CI: 30.6-63.9) with a specificity of 98.0% (95%CI: 96.8-98.7). The high specificity of oncoprotein tests supports its use for triaging HPV-positive women. However, oncoprotein-negative women would not be recommended to undertake routine screening, requiring further follow-up. Large-scale and longitudinal studies are needed to further investigate the role of E6/E7-oncoprotein detection in predicting the risk of developing cervical pre-cancer and cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-positive women.
METHODS
METHODS
We conducted a systematic review and meta-analysis assessing the accuracy of HPV-E6/E7-oncoprotein tests to detect underlying cervical-precancer and cancer. We included studies reporting data on oncoprotein test accuracy detecting cervical intraepithelial neoplasia grade 3 or worse. Random effects logistic regression models were applied for pooling absolute and relative accuracy.
RESULTS
RESULTS
Twenty-two studies were included. Sensitivity and specificity estimates ranged from 54.2% (95%CI: 45.2-63.0) to 69.5% (95%CI:60.8-76.9) and from 82.8% (95%CI: 50.4-95.8) to 99.1 (95%CI: 98.8-99.3), respectively in the population irrespective of HPV status. Higher sensitivity estimates ranging from 60.8% (95%CI: 49.6-70.9) to 75.5% (95%CI: 71.7-78.9) but lower specificity estimates ranging from 83.7% (95%CI: 76.1-89.3) to 92.1% (95%CI: 88.5-94.6) were observed in studies enrolling high-risk-HPV-positive women. Studies recruiting only HIV-positive women showed a pooled sensitivity of 46.9% (95%CI: 30.6-63.9) with a specificity of 98.0% (95%CI: 96.8-98.7).
CONCLUSIONS
CONCLUSIONS
The high specificity of oncoprotein tests supports its use for triaging HPV-positive women. However, oncoprotein-negative women would not be recommended to undertake routine screening, requiring further follow-up. Large-scale and longitudinal studies are needed to further investigate the role of E6/E7-oncoprotein detection in predicting the risk of developing cervical pre-cancer and cancer.
Identifiants
pubmed: 37973957
doi: 10.1038/s41416-023-02490-w
pii: 10.1038/s41416-023-02490-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2023. The Author(s).
Références
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11:e197–e206.
pubmed: 36528031
doi: 10.1016/S2214-109X(22)00501-0
Cancer Today GCO. Estimated number of new cases in 2020, worldwide, females, all ages 2020 [Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1 . Access Date: March 3, 2022.
Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40:602–8.
pubmed: 31500479
doi: 10.1080/01443615.2019.1634030
Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513–7.
pubmed: 18364507
doi: 10.1093/jnci/djn044
Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1–150.
pubmed: 19891902
doi: 10.3310/hta13510
Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582–9.
pubmed: 17471427
doi: 10.1086/516784
Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102:315–24.
pubmed: 20157096
pmcid: 2831050
doi: 10.1093/jnci/djq001
World Health Organization. New recommendations for screening and treatment to prevent cervical cancer 2021 [Available from: https://www.who.int/news/item/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer . Access Date: March 3, 2022.
Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817–26.
pubmed: 25936581
doi: 10.1016/j.cmi.2015.04.015
Arbyn M, Ronco G, Anttila A M, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–F99.
pubmed: 23199969
doi: 10.1016/j.vaccine.2012.06.095
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266–82.
pubmed: 24629334
pmcid: 3992243
doi: 10.1016/j.chom.2014.02.011
Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother. 2018;106:1537–56.
pubmed: 30119229
doi: 10.1016/j.biopha.2018.06.149
Boccardo E, Baldi CVM, Carvalho AF, Rabachini T, Torres C, Barreta LA, et al. Expression of human papillomavirus type 16 E7 oncoprotein alters keratinocytes expression profile in response to tumor necrosis factor-alpha. Carcinogenesis. 2010;31:521–31.
pubmed: 20042637
doi: 10.1093/carcin/bgp333
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–60.
pubmed: 20592731
doi: 10.1038/nrc2886
Giarrè M, Caldeira S, Malanchi I, Ciccolini F, Leão MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol. 2001;75:4705–12.
pubmed: 11312342
pmcid: 114225
doi: 10.1128/JVI.75.10.4705-4712.2001
Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci. 2018;19:1706.
pubmed: 29890655
pmcid: 6032416
doi: 10.3390/ijms19061706
McBride AA, Warburton A. The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog. 2017;13:e1006211.
pubmed: 28384274
pmcid: 5383336
doi: 10.1371/journal.ppat.1006211
Arbyn M, Simon M, Peeters E, Xu L, Meijer C, Berkhof J, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27:1083–95.
pubmed: 33975008
doi: 10.1016/j.cmi.2021.04.031
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.
pubmed: 19622552
pmcid: 2714672
doi: 10.1136/bmj.b2700
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Kwon Y, Lemieux M, McTavish J, Wathen N. Identifying and removing duplicate records from systematic review searches. J Med Libr Assoc. 2015;103:184–8.
pubmed: 26512216
pmcid: 4613377
doi: 10.3163/1536-5050.103.4.004
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
pubmed: 27919275
pmcid: 5139140
doi: 10.1186/s13643-016-0384-4
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
pubmed: 22007046
doi: 10.7326/0003-4819-155-8-201110180-00009
Nyaga VN, Arbyn M. Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data—a tutorial. Arch Public Health. 2022;80:95.
pubmed: 35351195
pmcid: 8962039
doi: 10.1186/s13690-021-00747-5
Ara R, Khatun S, Pervin S, Jahan M, Shahera U, Ferdous J, et al. Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. Gynecol Oncol. 2020;158:590–6.
pubmed: 32680634
doi: 10.1016/j.ygyno.2020.06.496
Agorastos T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, Skenderi A, Lekka I, et al. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study. Int J Cancer. 2017;141:519–30.
pubmed: 28470689
doi: 10.1002/ijc.30761
Chibwesha CJ, Frett B, Katundu K, Bateman AC, Shibemba A, Kapambwe S, et al. Clinical performance validation of 4 point-of-care cervical cancer screening tests in HIV-infected women in Zambia. J Low Genit Trac Dis. 2016;20:218–23.
doi: 10.1097/LGT.0000000000000206
Cuzick J, Ahmad AS, Austin J, Cadman L, Ho L, Terry G, et al. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4. J Clin Virol. 2016;82:145–51.
pubmed: 27498250
pmcid: 4994427
doi: 10.1016/j.jcv.2016.06.015
de Oliveira CM, Musselwhite LW, Pantano ND, Vazquez FL, Smith JS, Schweizer J, et al. Detection of HPV E6 oncoprotein from urine via a novel immunochromatographic assay. Plos One. 2020;15:e0232105.
pubmed: 32320451
pmcid: 7176116
doi: 10.1371/journal.pone.0232105
Ferrera A, Valladares W, Cabrera Y, de la Luz Hernandez M, Darragh T, Baena A, et al. Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. Int J Cancer. 2019;145:2042–50.
pubmed: 30684396
doi: 10.1002/ijc.32156
Kong L, Xiao X, Lou H, Liu P, Song S, Liu M, et al. Analysis of the role of the human papillomavirus 16/18 E7 protein assay in screening for cervical intraepithelial neoplasia: a case control study. BMC Cancer. 2020;20:999.
pubmed: 33054783
pmcid: 7559470
doi: 10.1186/s12885-020-07483-z
Mariano VS, Lorenzi AT, Scapulatempo C, Stein MD, Resende JCP, Antoniazzi M, et al. A low-cost HPV immunochromatographic assay to detect high-grade cervical intraepithelial neoplasia. Plos One. 2016;11:e0164892.
pubmed: 27764154
pmcid: 5072685
doi: 10.1371/journal.pone.0164892
Ndizeye Z, Menon S, Van Geertruyden J-P, Sauvaget C, Jacquemyn Y, Bogers J-P, et al. Performance of OncoE6 (TM) Cervical Test in detecting cervical precancer lesions in HIV-positive women attending an HIV clinic in Bujumbura, Burundi: a cross-sectional study. Bmj Open. 2019;9:e029088.
pubmed: 31494606
pmcid: 6731839
doi: 10.1136/bmjopen-2019-029088
Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014;134:2891–901.
pubmed: 24248915
doi: 10.1002/ijc.28616
Rezhake R, Hu SY, Zhao S, Xu XQ, Zhao XL, Zhang L, et al. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. Int J Cancer. 2019;144:34–42.
pubmed: 29943809
doi: 10.1002/ijc.31633
Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010;48:4646–8.
pubmed: 20926711
pmcid: 3008434
doi: 10.1128/JCM.01315-10
Sellors JW, Schweizer JG, Lu PS, Liu B, Weigl BH, Cui JF, et al. Association of elevated E6 oncoprotein with grade of cervical neoplasia using PDZ interaction-mediated precipitation of E6. J Low Genit Trac Dis. 2011;15:169–76.
doi: 10.1097/LGT.0b013e3181f6c84d
Shi WJ, Liu H, Wu D, Tang ZH, Shen YC, Guo L. E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population. Oncol Lett. 2017;14:6251–8.
pubmed: 29113275
pmcid: 5661417
Torres KL, Mariño JM, Pires Rocha DA, de Mello MB, de Melo Farah HH, Reis RDS, et al. Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A promising option for detection of cervical malignancies in remote areas. PLoS One. 2018;13:e0201262.
pubmed: 30036381
pmcid: 6056043
doi: 10.1371/journal.pone.0201262
Torres-Ibarra L, Lorincz AT, Wheeler CM, Cuzick J, Hernández-López R, Spiegelman D, et al. Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women. Int J Cancer. 2021;148:2264–73.
pubmed: 33252834
doi: 10.1002/ijc.33414
Valdez M, Jeronimo J, Bansil P, Qiao YL, Zhao FH, Chen W, et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural China. Int J Cancer. 2016;138:1453–61.
pubmed: 26421807
doi: 10.1002/ijc.29877
Wu ZN, Yu LL, Lei XQ, Qin Y, Zhang X, Chen W, et al. The association between human papillomavirus 16, 18 DNA load and E6 protein expression in cervical intraepithelial neoplasia and cancer. J Clin Virol. 2018;108:6–11.
pubmed: 30196013
doi: 10.1016/j.jcv.2018.08.008
Yang YS, Smith-McCune K, Darragh TM, Lai Y, Lin JH, Chang TC, et al. Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccin Immunol. 2012;19:1474–9.
doi: 10.1128/CVI.00388-12
Yu LL, Jiang MY, Qu PP, Wu ZN, Sun PS, Xi MR, et al. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage. Int J Cancer. 2018;143:813–22.
pubmed: 29524206
doi: 10.1002/ijc.31368
Zhang Q, Dong L, Hu S, Feng R, Zhang X, Pan Q, et al. Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017;141:1110–9.
pubmed: 28560716
doi: 10.1002/ijc.30807
Zhang Y, Sun L, Zhao H, Zhang Y, Wang L, Ma Z, et al. Application of human papillomavirus 16/18 E6 protein detection for cervical cancer screening. Cancer Res Clin. 2017;29:164–7.
Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res. 2013;6:938–48.
doi: 10.1158/1940-6207.CAPR-13-0091
Shukla S, Mahata S, Shishodia G, Pande S, Verma G, Hedau S, et al. Physical state & copy number of high risk human papillomavirus type 16 DNA in progression of cervical cancer. Indian J Med Res. 2014;139:531–43.
pubmed: 24927339
pmcid: 4078491
Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378–84.